When using Pramipexole-Teva, the following side effects are listed: abnormal behavior (symptoms of impulsive and compulsive actions) such as a tendency to overeating (hyperphagia), obsessive desire to shop (pathological shopping), hypersexuality and pathological craving for gambling, abnormal dreams, amnesia, confusion, constipation, delirium, dizziness, dyskinesia, dyspnoea, weakness, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, insomnia, libido disorders, t nausea, paranoia, peripheral edema, pneumonia, pruritus, rash and other hypersensitivity reactions, anxiety, drowsiness, sudden falling asleep, fainting, blurred vision (including diplopia, decreased visual acuity and clear perception), vomiting, weight loss, including decreased appetite .
The risk of a sharp decrease in blood pressure during therapy with Pramipexol-Teva is not higher than in the treatment of placebo. However, hypotension may occur in some patients at the beginning of treatment, especially if the dose is increased too quickly.With therapy with the drug Pramipexol-Teva, libido disorders (increase or decrease) can be associated.
Patients receiving pramipexole, reported a sudden fall asleep during daytime activity, including driving, which sometimes led to traffic accidents. At the same time, some of them did not report having anxious signs such as drowsiness, often observed in patients taking pramipexole tablets at doses above 1.5 mg per day, which, according to modern knowledge of the physiology of sleep, always lead to sudden falling asleep. A clear connection with the duration of treatment was not revealed. At the same time, some patients took other drugs with potentially sedative properties. In most cases where such information was available, there were no such episodes after a dose reduction or discontinuation of treatment.
Patients with Parkinson's disease who received dopamine agonist therapy, including pramipexole in high doses, reported a pathological craving for gambling, increased libido and hypersexuality, which usually occurred after a dose reduction or discontinuation of treatment.
From the nervous system: often confusion, insomnia, dizziness, impaired consciousness, depression, anxiety; infrequently extrapyramidal syndrome, amnesia, hypoesthesia, dystonia, myoclonus, tremor, ataxia, hypokinesia, delirium, suicidal mood; rarely - malignant neuroleptic syndrome (hyperthermia, muscle rigidity, akathisia, autonomic lability, disturbance of thinking).
From the musculoskeletal system: rarely - hypertension of muscles, leg muscle cramps, muscle twitching, arthritis, bursitis, myasthenia gravis, pain in the lumbosacral spine, pain in the chest, pain in the neck.
From the digestive system: often - decreased appetite, dysphagia, dyspepsia, abdominal pain, flatulence, diarrhea, dry mouth, vomiting.
From the respiratory system: infrequently - pharyngitis, sinusitis, rhinitis, shortness of breath, coughing, voice change; very rarely - flu-like syndrome, pulmonary infiltration, pleural effusion.
From the genitourinary system: rarely - urinary tract infection, frequency of urination.
From the cardiovascular system: often - orthostatic hypotension, infrequently - tachycardia, increased activity of creatine phosphokinase (CK), stenocardia, arrhythmias. In individual patients, lowering blood pressure may occur at the beginning of treatment, especially if the dose of the drug is increased too quickly.
From the sense organs: often - conjunctivitis, paralysis of accommodation, diplopia, cataract, increased intraocular pressure, hearing loss
Other: often - allergic reactions, increased body temperature, weight loss, increased sweating; rarely - retroperitoneal fibrosis. There were cases of development of peripheral edema.